The evaluation of positron emission tomography to assess pharmacodynamics and pharmacokinetics of anti cancer drugs

Positron emission tomography (PET) is a non-invasive imaging technique that is emerging as a useful tool in the field of cancer medicine particularly in drug development. The purpose of this thesis has been to perform clinical studies using two different radiotracers, 5-[^V]fIuorouracil (5-['^F...

Full description

Bibliographic Details
Main Author: Gupta, Nishi
Other Authors: Price, Pat ; Aboagye, Eric
Published: Imperial College London 2008
Subjects:
Online Access:http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.490369
id ndltd-bl.uk-oai-ethos.bl.uk-490369
record_format oai_dc
spelling ndltd-bl.uk-oai-ethos.bl.uk-4903692016-10-04T03:29:57ZThe evaluation of positron emission tomography to assess pharmacodynamics and pharmacokinetics of anti cancer drugsGupta, NishiPrice, Pat ; Aboagye, Eric2008Positron emission tomography (PET) is a non-invasive imaging technique that is emerging as a useful tool in the field of cancer medicine particularly in drug development. The purpose of this thesis has been to perform clinical studies using two different radiotracers, 5-[^V]fIuorouracil (5-['^F]FU) and 2-[''C]thymidine, to assess pharmacokinetic and pharmacodynamic parameters respectively, which were derived from PET imaging and to establish the contribution that PET can add to drug development, in vivo, in man. Aims: 1) Quantify the pharmacodynamic effects of cytotoxic agents in tumour and normal tissue using 2-["C]thymidine 2) Measure changes in tumour and normal tissue pharmacokinetics of 5-Fluorouracil in response to the modulating agents carbogen and nicotinamide or interferon 3) Assessment of blood flow change in tumour and normal tissue to carbogen and nicotinamide or interferon 4) Interpretation of PET data using novel analysis methods with modified Patlak and spectral analysis Methods: In the 5-['^]FU study, patients with metastatic gastrointestinal cancer underwent PET scanning at the start of 2 separate chemotherapy cycles. The 2nd scan was performed after the administration of carbogen and nicotinamide or interferon. In the 2-["C]thymidine study patients receiving chemotherapy were scanned before commencing chemotherapy, and 1 week after the 3''' cycle of chemotherapy. Patients also had conventional imaging before the start of and after 3 cycles of treatment. Findings: After carbogen and nicotinamide administration, 5-['^]FU uptake was increased in tumour, but not in normal tissue. Regional perfusion was elevated in tumours but decreased in kidneys after carbogen and nicotinamide. After interferon administration, there was an increase in 5-['^]FU retention in tumours, but no increase in uptake. Regional perfusion in tumour and normal tissue was unaltered by interferon. Retention of 2-["C]thymidine decreased in tumour in keeping with the results of conventional radiology, suggesting a pathological response, assessed in vivo, to chemotherapy.615.1Imperial College Londonhttp://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.490369http://hdl.handle.net/10044/1/40004Electronic Thesis or Dissertation
collection NDLTD
sources NDLTD
topic 615.1
spellingShingle 615.1
Gupta, Nishi
The evaluation of positron emission tomography to assess pharmacodynamics and pharmacokinetics of anti cancer drugs
description Positron emission tomography (PET) is a non-invasive imaging technique that is emerging as a useful tool in the field of cancer medicine particularly in drug development. The purpose of this thesis has been to perform clinical studies using two different radiotracers, 5-[^V]fIuorouracil (5-['^F]FU) and 2-[''C]thymidine, to assess pharmacokinetic and pharmacodynamic parameters respectively, which were derived from PET imaging and to establish the contribution that PET can add to drug development, in vivo, in man. Aims: 1) Quantify the pharmacodynamic effects of cytotoxic agents in tumour and normal tissue using 2-["C]thymidine 2) Measure changes in tumour and normal tissue pharmacokinetics of 5-Fluorouracil in response to the modulating agents carbogen and nicotinamide or interferon 3) Assessment of blood flow change in tumour and normal tissue to carbogen and nicotinamide or interferon 4) Interpretation of PET data using novel analysis methods with modified Patlak and spectral analysis Methods: In the 5-['^]FU study, patients with metastatic gastrointestinal cancer underwent PET scanning at the start of 2 separate chemotherapy cycles. The 2nd scan was performed after the administration of carbogen and nicotinamide or interferon. In the 2-["C]thymidine study patients receiving chemotherapy were scanned before commencing chemotherapy, and 1 week after the 3''' cycle of chemotherapy. Patients also had conventional imaging before the start of and after 3 cycles of treatment. Findings: After carbogen and nicotinamide administration, 5-['^]FU uptake was increased in tumour, but not in normal tissue. Regional perfusion was elevated in tumours but decreased in kidneys after carbogen and nicotinamide. After interferon administration, there was an increase in 5-['^]FU retention in tumours, but no increase in uptake. Regional perfusion in tumour and normal tissue was unaltered by interferon. Retention of 2-["C]thymidine decreased in tumour in keeping with the results of conventional radiology, suggesting a pathological response, assessed in vivo, to chemotherapy.
author2 Price, Pat ; Aboagye, Eric
author_facet Price, Pat ; Aboagye, Eric
Gupta, Nishi
author Gupta, Nishi
author_sort Gupta, Nishi
title The evaluation of positron emission tomography to assess pharmacodynamics and pharmacokinetics of anti cancer drugs
title_short The evaluation of positron emission tomography to assess pharmacodynamics and pharmacokinetics of anti cancer drugs
title_full The evaluation of positron emission tomography to assess pharmacodynamics and pharmacokinetics of anti cancer drugs
title_fullStr The evaluation of positron emission tomography to assess pharmacodynamics and pharmacokinetics of anti cancer drugs
title_full_unstemmed The evaluation of positron emission tomography to assess pharmacodynamics and pharmacokinetics of anti cancer drugs
title_sort evaluation of positron emission tomography to assess pharmacodynamics and pharmacokinetics of anti cancer drugs
publisher Imperial College London
publishDate 2008
url http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.490369
work_keys_str_mv AT guptanishi theevaluationofpositronemissiontomographytoassesspharmacodynamicsandpharmacokineticsofanticancerdrugs
AT guptanishi evaluationofpositronemissiontomographytoassesspharmacodynamicsandpharmacokineticsofanticancerdrugs
_version_ 1718386050472083456